<DOC>
	<DOCNO>NCT02731469</DOCNO>
	<brief_summary>BCD-131 pegylated darbepoetin beta . BCD-131-1 open clinical trial evaluate pharmacokinetics , pharmacodynamics , tolerance , safety immunogenicity single injection increase dos BCD-131 healthy volunteer compare Mircera速 Aranesp速 . Clinical trial conduct two stage . On first stage optimal dose therapeutic use BCD-131 determine ( subcutaneous injection ) . On second stage determine dose inject subcutaneously intravenously .</brief_summary>
	<brief_title>Clinical Trial Evaluate Pharmacokinetics , Pharmacodynamics , Tolerance , Safety Immunogenicity Single Injection Increasing Doses BCD-131 Healthy Volunteers Compared Mircera速 Aranesp速</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Volunteer healthy accord screen investigation , include absence history hematologic disease . Results hematological , biochemical blood analysis normal range , include serum ferritin , endogenous erythropoietin No history alcohol drug abuse . History use erythropoiesis stimulate agent . Acute hemorrhage , donation blood / plasma blood transfusion 2 month prior study enrollment . History chronic hemorrhage . History allergy excipients study drug . Current use drug history disease could influence study drug pharmacokinetics . Full list inclusion exclusion criterion find Protocol study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>